{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T20:36:55Z","timestamp":1786739815659,"version":"build-2736575974"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Over 2 million people worldwide are suffering from gene-related retinal diseases, inherited or acquired, and over 270 genes have been identified which are found to be responsible for these conditions. This review article touches upon the mechanisms of gene therapy, various enzymes of the visual cycle responsible for different genetic diseases, Luxturna\u2014the first US Food and Drug Administration (FDA)-approved therapeutic gene product, and several ongoing trials of gene therapy for age-related macular degeneration. Gene therapy has tremendous potential for retinal conditions due to its ease of accessibility, immune-privileged status, and tight blood-retinal barriers, limiting systemic side effects of the drug. In recent years, advances in gene therapy in retinal conditions have increasing significantly, with progress in cell-specific targeting and transduction efficiency of gene products through the use of adeno-associated viral vectors (AAVs), suggesting that even greater success in future clinical trials is possible.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3117_20","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:07:16Z","timestamp":1630537636000},"page":"2257-2265","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":49,"title":["Gene therapy in retinal diseases: A review"],"prefix":"10.4103","volume":"69","author":[{"given":"Deven","family":"Dhurandhar","sequence":"first","affiliation":[{"name":"Retina and Uveitis Department, GMR Varalakshmi Campus, LV Prasad Eye Institute, Visakhapatnam, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niroj Kumar","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, Kallam Anji Reddy Campus, L V Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indumathi","family":"Mariappan","sequence":"additional","affiliation":[{"name":"Centre for Ocular Regeneration, Hyderabad Eye Research Foundation, Kallam Anji Reddy Campus, L.V. Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, Kallam Anji Reddy Campus, L V Prasad Eye Institute, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1006\/mthe.2002.0525","article-title":"A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus","volume":"5","author":"Anand","year":"2002","journal-title":"Molecular therapy"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fimmu.2013.00261","article-title":"Immunology of AAV-mediated gene transfer in the eye","volume":"4","author":"Willett","year":"2013","journal-title":"Front immunol"},{"issue":"Suppl-6","key":"B3-20240828","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5301\/EJO.2010.6049","article-title":"Blood-retinal barrier","volume":"21","author":"Cunha-Vaz","year":"2011","journal-title":"Eur J Ophthalmol"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"634351","DOI":"10.1155\/2013\/634351","article-title":"Multimodal imaging in hereditary retinal diseases","volume":"2013","author":"Pichi","year":"2013","journal-title":"J Ophthalmol"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1146\/annurev.pharmtox.47.120505.105225","article-title":"Diseases caused by defects in the visual cycle:Retinoids as potential therapeutic agents","volume":"47","author":"Travis","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1074\/jbc.274.6.3834","article-title":"Molecular and biochemical characterization of lecithin-retinol acyltransferase","volume":"274","author":"Ruiz","year":"1999","journal-title":"J Biol Chem"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"10422","DOI":"10.1074\/jbc.M312410200","article-title":"Lecithin-retinol acyltransferase is essential for accumulation of all-trans-retinyl esters in the eye and in the liver","volume":"279","author":"Batten","year":"2004","journal-title":"J Biolo Chem"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1167\/iovs.12-9548","article-title":"Early onset retinal dystrophy due to mutations in LRAT:Molecular analysis and detailed phenotypic study","volume":"53","author":"Borman","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1371\/journal.pmed.0020333","article-title":"Pharmacological and rAAV gene therapy rescue of visual functions in a blind mouse model of Leber congenital amaurosis","volume":"2","author":"Batten","year":"2005","journal-title":"PLoS Med"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"13658","DOI":"10.1073\/pnas.0504167102","article-title":"Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle","volume":"102","author":"Redmond","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/humu.20010","article-title":"Leber congenital amaurosis:Comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, and genotype\u2013phenotype correlations as a strategy for molecular diagnosis","volume":"23","author":"Hanein","year":"2004","journal-title":"Hum Mutat"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/nu8110746","article-title":"Retinol dehydrogenases regulate vitamin a metabolism for visual function","volume":"8","author":"Sahu","year":"2016","journal-title":"Nutrients"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.preteyeres.2008.05.003","article-title":"Leber congenital amaurosis:Genes, proteins and disease mechanisms","volume":"27","author":"den Hollander","year":"2008","journal-title":"Prog Retin Eye Res"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.exer.2010.08.013","article-title":"Retinol dehydrogenases (RDHs) in the visual cycle","volume":"91","author":"Parker","year":"2010","journal-title":"Exp Eye Res"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/humu.9485","article-title":"Spectrum of NPHP6\/CEP290 mutations in Leber congenital amaurosis and delineation of the associated phenotype","volume":"28","author":"Perrault","year":"2007","journal-title":"Hum Mutat"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1167\/iovs.06-0628","article-title":"The phenotype of early-onset retinal degeneration in persons with RDH12 mutations","volume":"48","author":"Schuster","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s13353-015-0281-x","article-title":"Fundus albipunctatus:Review of the literature and report of a novel RDH5 gene mutation affecting the invariant tyrosine (p. Tyr175Phe)","volume":"56","author":"Skorczyk-Werner","year":"2015","journal-title":"J Appl Genet"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/jcp.1041170308","article-title":"The presence of a soluble interphotoreceptor retinol-binding protein (IRBP) in the retinal interphotoreceptor space","volume":"117","author":"Pfeffer","year":"1983","journal-title":"J Cell Physiol"},{"key":"B19-20240828","first-page":"2275","article-title":"Purification of the full-length Xenopus interphotoreceptor retinoid binding protein and growth of diffraction-quality crystals","volume":"13","author":"Ghosh","year":"2007","journal-title":"Mol Vis"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1167\/iovs.08-2497","article-title":"A homozygous missense mutation in the IRBP gene (RBP3) associated with autosomal recessive retinitis pigmentosa","volume":"50","author":"den Hollander","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1167\/iovs.15-16520","article-title":"Lack of interphotoreceptor retinoid binding protein caused by homozygous mutation of RBP3 is associated with high myopia and retinal dystrophy","volume":"56","author":"Arno","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-417197-8.00001-8","article-title":"Constitutively active rhodopsin and retinal disease","volume":"70","author":"Park","year":"2014","journal-title":"Adv Pharmacol"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1073\/pnas.44.2.130","article-title":"The action of light on rhodopsin","volume":"44","author":"Hubbard","year":"1958","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","article-title":"The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints","volume":"63","author":"Fredriksson","year":"2003","journal-title":"Mol Pharmacol"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0039-6257(02)00336-3","article-title":"Gene therapy for genetic and acquired retinal diseases","volume":"47","author":"Chaum","year":"2002","journal-title":"Surv Ophthalmol"},{"key":"B26-20240828","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/sj.gt.3302812","article-title":"Gene therapy progress and prospects:The eye","volume":"13","author":"Bainbridge","year":"2006","journal-title":"Gene Ther"},{"key":"B27-20240828","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/genes10040287","article-title":"Adeno-associated viral vectors as a tool for large gene delivery to the retina","volume":"10","author":"Trapani","year":"2019","journal-title":"Genes"},{"key":"B28-20240828","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes:Vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol Ther"},{"key":"B29-20240828","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.visres.2007.07.027","article-title":"Versatility of AAV vectors for retinal gene transfer","volume":"48","author":"Surace","year":"2008","journal-title":"Vision Res"},{"key":"B30-20240828","first-page":"456","article-title":"Nonviral ocular gene therapy:Assessment and future directions","volume":"10","author":"Conley","year":"2008","journal-title":"Curr Opin Mol Ther"},{"key":"B31-20240828","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1167\/iovs.05-0165","article-title":"Vitreous:A barrier to nonviral ocular gene therapy","volume":"46","author":"Peeters","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B32-20240828","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/77068","article-title":"Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy","volume":"25","author":"Ali","year":"2000","journal-title":"Nat Genet"},{"key":"B33-20240828","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/hmg\/9.4.645","article-title":"Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat","volume":"9","author":"D'Cruz","year":"2000","journal-title":"Hum Mol Genet"},{"key":"B34-20240828","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1073\/pnas.221364198","article-title":"Correction of the retinal dystrophy phenotype of the RCS rat by viral gene transfer of Mertk","volume":"98","author":"Vollrath","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B35-20240828","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1479-0556-2-3","article-title":"Recombinant adeno-associated virus type 2-mediated gene delivery into the Rp.e65(-\/-) knockout mouse eye results in limited rescue","volume":"2","author":"Lai","year":"2004","journal-title":"Genet Vaccines Ther"},{"key":"B36-20240828","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1076\/opge.24.2.75.13996","article-title":"The gene for Stargardt disease, ABCA4, is a major retinal gene:A mini-review","volume":"24","author":"Koenekoop","year":"2003","journal-title":"Ophthalmic Genet"},{"key":"B37-20240828","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1172\/JCI34316","article-title":"Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice","volume":"118","author":"Allocca","year":"2008","journal-title":"J Clin Invest"},{"key":"B38-20240828","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14712598.2017.1356817","article-title":"Gene therapy for age-related macular degeneration","volume":"17","author":"Moore","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"B39-20240828","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/bjo.79.7.697","article-title":"X linked retinoschisis","volume":"79","author":"George","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"B40-20240828","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"B41-20240828","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat Protoc"},{"key":"B42-20240828","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber's congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N Engl J Med"},{"key":"B43-20240828","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2016.10.044","article-title":"CRISPR-based technologies for the manipulation of eukaryotic genomes","volume":"168","author":"Komor","year":"2017","journal-title":"Cell"},{"key":"B44-20240828","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00417-008-0926-0","article-title":"Resolving the clinical acuity categories \u201chand motion\u201cand \u201ccounting fingers\u201cusing the Freiburg Visual Acuity Test (FrACT)","volume":"247","author":"Lange","year":"2009","journal-title":"Graefes Archive Clin Exp Ophthalmol"},{"key":"B45-20240828","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy:A randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"B46-20240828","first-page":"751","article-title":"Global prevalence and causes of visual impairment with special reference to the general population of Saudi Arabia","volume":"34","author":"Alswailmi","year":"2018","journal-title":"Pak J Med Sci"},{"key":"B47-20240828","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/hum.2006.17.167","article-title":"Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration:Results of a phase I clinical trial","volume":"17","author":"Campochiaro","year":"2006","journal-title":"Hum Gene Ther"},{"key":"B48-20240828","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ebiom.2016.11.016","article-title":"Phase 2a randomized clinical trial:Safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration","volume":"14","author":"Constable","year":"2016","journal-title":"EBioMedicine"},{"key":"B49-20240828","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ajo.2017.02.018","article-title":"Gene therapy in neovascular age-related macular degeneration:Three-Year Follow-up of a phase 1 Randomized Dose Escalation Trial","volume":"177","author":"Constable","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"B50-20240828","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(17)30979-0","article-title":"Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration:A phase 1, open-label trial","volume":"390","author":"Heier","year":"2017","journal-title":"Lancet"},{"key":"B51-20240828","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.gt.3301878","article-title":"Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model","volume":"10","author":"Igarashi","year":"2003","journal-title":"Gene therapy"},{"key":"B52-20240828","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11373-007-9153-7","article-title":"Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model","volume":"14","author":"Lai","year":"2007","journal-title":"J Biomed Sci"},{"key":"B53-20240828","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/hum.2016.117","article-title":"Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study","volume":"28","author":"Campochiaro","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B54-20240828","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ymthe.2017.12.002","article-title":"AAV8-antiVEGFfab ocular gene transfer for neovascular age-related macular degeneration","volume":"26","author":"Liu","year":"2018","journal-title":"Mol Ther"},{"key":"B55-20240828","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.144.9.3478","article-title":"The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9","volume":"144","author":"Rollins","year":"1990","journal-title":"J Immunol"},{"key":"B56-20240828","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Mol Ther"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3117_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:33:55Z","timestamp":1786736035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3117_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3117_20","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"2020-10-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}